Faecal haemoglobin concentration, a good predictor of risk of advanced colorectal neoplasia in symptomatic and asymptomatic patients by Navarro, M. et al.
  
 
FAECAL HAEMOGLOBIN CONCENTRATION, A GOOD
PREDICTOR OF RISK OF ADVANCED COLORECTAL
NEOPLASIA IN SYMPTOMATIC AND ASYMPTOMATIC
PATIENTS.
 
Mercedes Navarro1, Gonzalo Hijos1, Teresa Ramirez2, Ignacio Omella3, Patricia
Carrera-Las Fuentes1, Angel Lanas4, 1*
 
1Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
(CIBERehd), Spain, 2Service of Pathology, Aragon Institute for Health Research (IIS
Aragon), Spain, 3School of Medicine, University of Zaragoza, Spain, 4Department of
Medicine, University of Zaragoza, Spain
 Submitted to Journal:
 Frontiers in Medicine
 Specialty Section:
 Gastroenterology
 ISSN:
 2296-858X
 Article type:
 Original Research Article
 Received on:
 27 Dec 2018
 Accepted on:
 12 Apr 2019
 Provisional PDF published on:
 12 Apr 2019
 Frontiers website link:
 www.frontiersin.org
 Citation:
 
Navarro M, Hijos G, Ramirez T, Omella I, Carrera-las_fuentes P and Lanas A(2019) FAECAL
HAEMOGLOBIN CONCENTRATION, A GOOD PREDICTOR OF RISK OF ADVANCED COLORECTAL NEOPLASIA IN
SYMPTOMATIC AND ASYMPTOMATIC PATIENTS.. Front. Med. 6:91. doi:10.3389/fmed.2019.00091
 Copyright statement:
 
© 2019 Navarro, Hijos, Ramirez, Omella, Carrera-las_fuentes and Lanas. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution and reproduction in other forums is permitted, provided the original author(s) or
licensor are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Pro is
ional
 
This Provisional PDF corresponds to the article as it appeared upon acceptance, after peer-review. Fully formatted PDF
and full text (HTML) versions will be made available soon.
 
Frontiers in Medicine | www.frontiersin.org
Provis
ional
  
 Conflict of interest statement
 The authors declare a potential conflict of interest and state it below.
 
Mercedes Navarro, Gonzalo Hijos, Teresa Ramirez,  Ignacio Omella, and  Patricia Carrera-Lasfuentes declare no conflicts of interest. Angel
Lanas is Advisor to Sysmex Iberia (Barcelona. Spain).
Provis
ional
FAECAL HAEMOGLOBIN CONCENTRATION, A GOOD 
PREDICTOR OF RISK OF ADVANCED COLORECTAL 
NEOPLASIA IN SYMPTOMATIC AND ASYMPTOMATIC 
PATIENTS. 
Authors: Mercedes Navarro1, Gonzalo Hijos1, Teresa Ramirez2, Ignacio Omella3, 
Patricia Carrera-Lasfuentes2, Ángel Lanas1,3,4,5 
Affiliation: 
1. Service of Digestive Diseases, University Clinic Hospital. Zaragoza. Spain 
2. Service of Pathology. University Clinic Hospital. Zaragoza. Spain. 
3. University of Zaragoza. Zaragoza. Spain 
4. CIBERehd, Madrid. Spain 
5. IIS Aragón. Zaragoza. Spain 
 
Address Correspondence: 
Angel Lanas 
Service of Digestive Diseases  
University Hospital Lozano Blesa 
50009 Zaragoza, Spain 
  
Provis
ional
ABSTRACT 
Background. Periodical faecal immunochemical testing (FIT) is a cost-effective strategy 
in colon cancer screening programmes. FIT is also used as a diagnostic test in 
symptomatic patients, but data are scarce. 
Aim. To determine the association between FIT-Hb concentration and the risk of 
advanced neoplasia (AN) detected in colonoscopy in two different populations. 
Methods. The outcomes of colonoscopies performed after a positive FIT (> 117 ng/ml) 
(Sentinel Gold test) result were analysed in patients included within a population-based 
CRC screening programme (screening group) and, as diagnostic evaluation in 
symptomatic patients (symptomatic group). The study was performed between  January 
1st,2014 and October 31,2016. Data are reported as medians with interquartile ranges or 
frequencies and percentages. Positive predictive value (PPV) at arbitrary faecal 
haemoglobin concentrations were also reported calculated for AN.  
Results. We recruited 2742 patients who underwent a colonoscopy procedure, 1515 
(53.5%) of them within the CRC screening programme. Patients in the screening group 
were younger (65.0±3.3 vs 66.2±13.4 years, p<0.001) and more frequently male  
(p<0.001) vs. the symptomatic group. Colonoscopy found more frequently neoplastic 
lesions in the screening compared to the symptomatic group (61.9% vs 44.8% p<0.001). 
Hb concentration in FIT was significantly higher in patients with AN compared with 
patients without AN in both groups (p<0.001). The age-adjusted risk of AN increased 
significantly in both groups according to FIT Hb concentration in the Quartile 3 (OR 
(95% CI): 2.94 (2.33–3.71) and Quartile 4 (OR: 5.52 (4.36–6.99). Males, in both groups 
showed a higher probability of presenting AN. FIT values were higher for left- than for 
right-sided AN in the screening, but not in the symptomatic  group. Positive predictive 
values for AN were higher in the screening group in positive FIT tests (range 43.9% - 
70.5%; 117 to > 1000 ng/ml) compared to those in the symptomatic group (36.3% – 
52.5%). Similar trends were observed for cancer diagnosis alone.  
Conclusions. Male gender, age and FIT Hb concentration are predictors of risk of 
advanced adenoma and colorectal cancer and can be used to prioritise colonoscopy in 
patients with suspected advanced neoplasia, both in screening and in symptomatic 
patients. 
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BACKGROUND. 
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide, 
being ranked in prevalence as the third in men and second in women. There are large 
variations in its incidence and mortality among regions [1]. As screening appears to be 
cost-effective compared to non-screening [2-4], population-based screening programmes 
have been implemented around the world in the past years [5-6]. Between them, the most 
common test used as a screening tool in organised screening programmes was the faecal 
occult blood test, being the faecal immunochemical test (FIT) the most commonly used 
[6]. On the other hand, as FIT is a user-friendly test, that only requires a single sample, 
without prior dietary restrictions needed [7], is being more frequently used in clinical 
practice as a diagnostic test for evaluation of patients that refer gastrointestinal symptoms 
such as change in bowel habits, diarrhoea, abdominal pain or anaemia prior to 
colonoscopy [8-10]. 
Lately, due to the increase in the participation in screening programmes and the sensitivity 
of the test compared to the guaiac based faecal occult blood test previously used, there 
has been an increase in the demand for colonoscopies, which has resulted in longer 
waiting times for patients. Prioritisation of patients with a higher risk for presenting an 
advanced colorectal neoplasia (AN) based on analytic or clinical parameters could 
mitigate a potential negative impact on waiting lists and on patients’ prognosis.  
As FIT is a quantitative test, a cut-off value can be chosen to adapt each local programme 
to the availability of endoscopic resources [11-12]. Recent studies suggest faecal 
haemoglobin concentration detected in the test can be a predictor of risk of advanced 
colorectal neoplasia in screening programmes [13-20] and could be used with other 
variables to stratify the risk of patients prior to colonoscopy in patients with symptoms, 
but data is still scarce [21-23] and no studies have compared both strategies in the same 
area of influence. In this study we seek to determine the association between FIT Hb 
concentration and the risk and positive predictive values of advanced neoplasia detected 
in colonoscopy in two different populations, symptomatic patients and people undergoing 
colonoscopy within a population–based CRC screening programme. 
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METHODS. 
Study population 
This retrospective observational study consisted of patients referred to a general tertiary 
hospital between 1 January 2014 and 31 October 2016 for colonoscopy after a positive 
FIT performed in two different scenarios: 
- Screening group: asymptomatic patients aged 60-69 years old included within a 
population-based CRC screening programme who tested positive for FIT. 
- Symptomatic group: patients referred for colonoscopy due to gastrointestinal 
symptoms (e.g. alterations of bowel habits, constipation, anaemia, diarrhoea, etc..) 
who also tested positive for FIT as a diagnostic evaluation prior to colonoscopy. 
Exclusion criteria in the screening group were as follows: personal history of CRC, 
adenoma or inflammatory bowel disease, familiar history of hereditary CRC or severe co-
existing illness.  There were no exclusion criteria in the symptomatic group if tested 
positive for FIT. FIT negative patients were not included in the study 
Faecal immunochemical test 
Patients were instructed how to collect a faecal sample according to the written 
instructions given with the commercial kit, which included no dietary or medication 
restrictions. The faecal material was collected in a sampling tube and analysed using 
FOB-GOLD® (Sentifit; Sysmex-Sentinel Ch SpA, Barcelona, Spain). The cut-off value 
applied was 117 ng/ml of buffer (equivalent to 20 micrograms of Hb per gram of faeces). 
Colonoscopy, histologic examination and definitions 
Colonoscopies were performed by experienced gastroenterologists of the Service of 
Digestive Diseases of our center. Polypoid lesions detected in the procedure were 
removed and classified according to the Spanish Network of Cancer Screening Programs 
(Red de Programas de Cribado de Cancer; http://www.cribadocancer.es/) which was 
based on the European guidelines for quality assurance in colorectal cancer screening and 
diagnosis) [24] by an experienced pathologist. Classification included “Low-risk 
adenomas” defined as 1-2 tubular adenomas <1 cm with low grade dysplasia; 
“Intermediate-risk adenomas” defined as ≥3 adenomas, or those ≥1cm, villous histology 
or high grade dysplasia; and  “High-risk adenomas” defined as ≥10 adenomas or those ≥2 
cm. Advanced neoplasia was defined by the European Society of Gastrointestinal 
Endoscopy (ESGE) [25]  as the presence of colorectal cancer or colorectal adenoma with 
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villous histology or high grade dysplasia or > 10 mm in size, which includes both the 
intermediate- and high-risk adenomas defined above. Tumour staging was established 
according to TNM classification system of the Union for International Cancer Control 
[26]. In this study we have considered right-sided lesions included those found in the 
cecum, ascending colon, hepatic flexure and proximal transverse colon. Left-sided lesions 
included those found in the sigmoid, descending colon, splenic flexure and distal 
transverse colon. Rectal lesions were identified in a different group, but reported together 
here together as left-sided colorectal lesions. 
Endpoint of the study 
The primary endpoint was to establish the association between the haemoglobin 
concentration detected in the faecal immunochemical test and the risk of advanced 
neoplasia, as defined above by the ESGE, found in the colonoscopy in the two different 
populations. Secondary endpoints were: 
- To evaluate the risk of colorectal cancer according to FIT concentrations 
- To evaluate the positive predictive value of different cut-off values of FIT for 
cancer, cancer + high-risk adenoma and cancer + high-risk + intermediate-risk 
adenoma, globally and in each group. 
- To identify additional independent risk factors for advanced neoplasia. 
Statistical analysis 
Continuous variables were reported as mean with standard deviation (SD) or median with 
interquartile range (IQR), whereas qualitative variables were expressed as frequencies 
and percentages. The relationship between qualitative variables was analysed by 
contingency tables with Chi-square test. The Kruskal–Wallis test was performed to 
evaluate differences in faecal haemoglobin concentrations among groups of individuals 
with different colonoscopy findings. The Mann–Whitney U test was used to compare 
differences between two independent groups. The positive predictive value (PPV) at 
arbitrary faecal hemoglobin concentrations was calculated for advanced colorectal 
neoplasia. A logistic regression analysis was performed to determine the independent 
association of sex, age and FIT quartiles with the detection of AN; ORs (IC95%) were 
reported. For all tests, a two-sided p value less than 0.05 was considered statistically 
significant. The statistical analysis was performed using the SPSS software v 22.0 for 
Windows (SPSS Ibérica, Madrid, Spain). 
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 RESULTS. 
A total of 2742 patients were included in the study, 1515 in the CRC screening group 
(55.3%) and 1227 (44.7%) in the symptomatic group. More men than women participated 
in the study (57.8% men; 1585). The mean age of patients was 65.6±9.3 years old, with 
the youngest being 18 and the eldest 100 years old. In the screening group, patients were 
younger (65.0±3.3 vs 66.2±13.4 years, p<0.001) and more frequently male (61.5% vs 
53.3%, p<0.001) compared to the symptomatic group (Table 1). Neoplastic lesions were 
found in colonoscopies more frequently in the screening group than in the symptomatic 
group (61.9% vs 44.8%, p<0.001) (Table 1). 
Faecal haemoglobin concentration according to colonoscopy findings 
There were statistically significant differences between Hb concentrations in FIT and 
endoscopic findings, both among the different lesions within each group (the higher the 
severity of the lesion, the higher the FIT value) and between groups. Overall, 
haemoglobin FIT values were higher in the symptomatic group (p<0.05), except for high-
risk adenomas (Table 2).  
Colonoscopy showed that 40.3% of the population of the study had AN, 35.8% in 
symptomatic group (27.1% left-sided, 8.7% right-sided)), and 43.9% in the population-
based screening programme (23.4% left-sided,18.8% right-sided) (p<0.001). Faecal 
haemoglobin values were statistically different between those patients who had or did not 
have AN or cancer alone, in each group (Table 3). 
Risk stratification for advanced colorectal neoplasia  
With regard to quartile values, patients were classified in four groups, according to their 
faecal haemoglobin concentration in FIT, and the risk of advanced neoplasia, considering 
Q1 as the reference group. As shown in Table 4A, the risk of AN was higher as the faecal 
haemoglobin concentration increased, globally and in each group separately. A similar 
pattern was observed when colorectal cancer was considered alone as an outcome, 
although statistically significance was not reached for Q3 in the screening group and both 
ranges and ORs were a bit higher in the symptomatic group (Table 4B). 
 
Findings of colonoscopies were also different according to quartiles of the faecal 
haemoglobin concentration, globally and in each group. The proportion of patients with 
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cancer or a high-risk adenoma increased progressively with each quartile from Q1 to Q4 
(Figure 1). 
Effect of age and sex on the risk of advanced neoplasia  
The mean age of patients was significantly different according to the colonoscopy 
findings in the symptomatic group (p<0.001), but not in the screening group (p=0.075), 
probably due to the characteristics of the study population invited to the programme 
which was between 60 and 69 years old (data not shown). More severe endoscopic 
findings were observed in elder patients. In the symptomatic group, the adjusted-risk of 
presenting advanced neoplasia increased 1.01 (CI95%;1.009-1.02) times per each 
additional year. 
Patients older than 60 years old in the symptomatic group had 1.84 (CI 95%; 1.39-2.44) 
times more risk of presenting an advanced neoplasia than younger ones, whereas in the 
screening group the risk was 1.04 (CI95%; 0.52-1.94). 
Sex was also found to be an independent risk factor of presenting advanced neoplasia, 
both globally and in each group (p<0.001). The proportion of men increases with the 
severity of endoscopic lesion (data not shown). Globally, men presented 2.72 (CI95% 
2.31-3.20) times more risk of presenting an advanced neoplasia than women. Similar 
findings were obtained when each group was analysed separately, 2.66 (CI95% 2.13-
3.31) in the screening group, and 2.68 (2.10-3.34) in the symptomatic group. In the 
multivariate analysis, the risk of presenting an advanced neoplasia was higher in the male 
group and in patients with the highest values of haemoglobin concentration in the FIT 
(Table 5A). Similar trends can be observed when cancer was analysed as a single 
outcome (Table 5B), but risk differences are stronger for both men and women in the 
symptomatic group. 
Faecal haemoglobin concentration according to colonoscopy findings location 
FIT concentration was also evaluated according to AN location.  Rectal lesions were 
included in the left-sided group because considering them separately no differences were 
found. There were statistically significant differences between Hb concentrations in FIT 
and  tumour location, both among the different locations within each group and between 
groups. FIT values were higher in the symptomatic group compared to the screening 
group both for left- and right-sided AN. Patients in the screening group that presented 
left-sided AN had a significantly higher faecal haemoglobin concentration than those with 
right-sided AN (p = 0.034).  The risk of AN based on quartiles was always higher for men 
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than for women (data not shown). No differences in haemoglobin values were detected 
among left- and right-sided lesions in the symptomatic group. (Table 6A).  When CRC 
location was evaluated, a similar pattern was observed, but there were no differences 
among left-sided and right-sided CRC FIT values, neither in symptomatic patients 
(p=0.426), nor in the screening group (p=0.451) (Table 6B). 
 
Positive predictive value (PPV) of FIT for advanced neoplasia 
Finally, we calculated the PPV of FIT for cancer and advanced adenoma plus cancer 
(equivalent to advanced neoplasia) using different cut-off values of faecal haemoglobin 
concentration. As it can be observed in the next figure, PPV increases with higher values 
of FIT, in each group (Figure 2).  
 
DISCUSSION. 
A significant correlation between faecal haemoglobin concentration detected in FIT and 
the findings of the colonoscopy has been observed in our study, with the amount of 
haemoglobin detected being higher in the patients with advanced lesions, data consistent 
with prior studies [13-20].  Unlike these studies, here we have shown, in the same study 
and within the same clinical and laboratory conditions, that these findings can apply not 
only to the screening group [15-18], but also in patients who referred symptoms [14], 
which should encourage the use of the FIT in clinical practice as an evaluation of 
symptomatic patients prior to colonoscopy. This is an important finding since 
colonoscopy is always planned to be performed below a specified limit of time after 
testing positive for FIT in screening programs, but this is not the case in patients with 
symptoms. In this population, FIT still needs to be positioned compared to symptoms in 
many public, and even private health systems, with waiting lists for colonoscopy which 
are common due to the growing workload with the implementation of CRC screening 
programmes and open access to primary care [6, 27-29].  
The median faecal haemoglobin value followed an increasing trend according to the 
severity of the pathology detected in colonoscopy. In cancer, high-risk adenoma, 
intermediate-risk adenoma and low-risk adenoma the concentration was always higher 
than in the prior step in both groups, with the only exception of non-neoplastic lesions 
compared to low-risk adenoma. These results were justifiable, since non-neoplastic 
lesions included pathologies that might be presented with bleeding, such as inflammatory 
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bowel disease, haemorrhoids or diverticular disease. Other studies have already reported 
that faecal Hb concentration is related to the presence and severity of lesions, mostly in 
patients with no symptoms within screening programs [16, 17, 18, 23, 30]. However, our 
study provides information for both symptomatic and asymptomatic patients and a more 
detailed analysis of fecal Hb concentration and risks for each type of neoplastic lesion 
than that reported in former studies. We show similar risk estimates for AN and cancer in 
both populations, but symptomatic patients had higher Hb faecal values, which suggests 
that prediction models based on actual concentration of faecal Hb may need to be different 
for each population. In our study we cannot provide figures for either specificity or 
negative predictive values, since our cohorts do not include patients with colonoscopy 
and negative FIT.  Like in our study, Auge et al. [18] analysed FIT positive patients in 
one of the Spanish CRC screening programs. They reported similar PPV to those found 
in our study, although we could show that figures where a bit different between 
symptomatic (lower values) and asymptomatic patients (higher values) for AN and the 
opposite for colorectal cancer. 
Age and sex have also been proved to be independent risk factors for AN [18]. Here we 
show a statistically significant difference in the results of colonoscopies according to sex 
in both groups, and to age in the symptomatic group. These differences were not detected 
in the asymptomatic population probably due to age limitations in the screening 
programme in our region. Unlike previous studies [16, 17, 23, 30] we show a more 
detailed analysis of that risk and provide higher risk values than those reported by Auge 
et al [18] in asymptomatic patients. A combination of sex and faecal haemoglobin 
concentration led to 4 risk categories with different probabilities of presenting an AN, 
both in screening and symptomatic patients. The patients with the highest risk of 
presenting AN were male and those with the highest haemoglobin concentration values 
in the FIT. These findings could be useful to prioritise those individuals with the greatest 
risk of presenting an AN or cancer in the colonoscopy, especially in centres with large 
waiting lists.  
 
In this line, several prediction models for symptomatic patients have been developed 
recently, such as the COLONPREDICT [22], that involved 11 variables (including faecal 
haemoglobin ≥20 μg/g), and obtained an area under the curve (AUC) = 0.92 (95%CI: 
0.91-0.94); or FAST Score [21], a more simple and friendly user model involving FIT 
haemoglobin concentration, age and sex, with promising results (AUC for CRC detection 
= 0.88 (CI95%: 0.85-0.90)).  Our results are in line with the FAST score [21] and outline 
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that probably a reliable prediction model with these 3 simple variables (faecal Hb 
concentration, sex and age) can be constructed.  However, in these studies only the risk 
of presenting CRC was evaluated. According to our results, faecal haemoglobin 
concentration could also be used, not only to calculate the risk of CRC, but also AN (CRC 
plus advanced adenoma). These two scores [21, 22] were validated in symptomatic 
patients, but similar models with the 3 above mentioned variables could be useful in 
asymptomatic patients. The evaluation of other variables such as the main symptom, 
smoking habit, nutritional practice or body mass index, that have not been evaluated in 
the present study, could also be interesting in the future to continue developing prediction 
models for advanced neoplasia, but probably the most important and determinant factor 
will be Hb concentration in FIT. It is possible that adding other measurements such as 
faecal calprotectin [31] to FIT could improve the diagnostic yield for AN or CRC, but 
this still need to be proved [32]. Risk-stratification models could also be useful to increase 
the awareness of endoscopists during the procedure about the probability of finding an 
AN, which could also improve quality indicators such as the adenoma detection rate, 
strongly correlated with the probability of presenting an interval CRC [33,34]. 
 
On the other hand, it is important to highlight that the risk of presenting advanced 
neoplasia was similar in the screening group compared to symptomatic patients in the 
same quartile of haemoglobin concentration detected in the test. Considering colorectal 
cancer alone both age-adjusted by sex, the risk of presenting CRC was  higher in patients 
who referred symptoms, compared to the asymptomatic ones, but trends showed a similar 
pattern to those seen for AN. These findings should encourage prioritising symptomatic 
patients with a high haemoglobin concentration detected in the FIT.  
Unlike other studies [14, 17, 18, 21, 22, 23, 30] we report data on FIT values for each 
type of lesion when colon location is considered. For AN we show higher faecal 
haemoglobin values in left-sided lesions compared to right-sided in the screening group. 
However, FIT values were similar in both locations in symptomatic patients, what also 
occurred with CRC location, in both groups. These data suggest that perhaps for right-
sided lesions in screening programs current cut-off values may have different sensitivity 
and PPVs.  
Adjusting the cut-off value of FIT to the available endoscopic resources is an alternative 
and may be a necessity. Positive predictive value for the different neoplastic lesions was 
higher when a higher haemoglobin cut-off point was established. Our study showed that 
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a positive FIT (> 117 ng/mL) established a 43.9% and 36.3% probability of presenting an 
advanced adenoma in the screening and symptomatic groups, which raised up to 62.1% 
and 48.7% respectively modifying the cut-off point to 500 ng/mL. 
The study has limitations such as the data collection which were collected retrospectively, 
which limits the main reason and actual symptoms for which the colonoscopy procedure 
was demanded in the symptomatic group. The construction of appropriate algorithms to 
automatically classify patients to be prioritised based on the risk of presenting advanced 
lesions may require that information. In the screening group the age range used is the 
main limitation, but it was due to the current health policy followed in our regional health 
system in which the programme was started in patients within this age range as a first 
step. However, this limitation has made that both populations had a closer age range. We 
believe that the data agree widely in both populations and these limitations do not 
invalidate our conclusions. 
 
CONCLUSIONS 
The amount of haemoglobin in the faecal immunochemical blood test correlates with the 
risk of finding neoplastic pathology in the colonoscopy in both asymptomatic and 
symptomatic patients. Due to the poor sensitivity of symptoms to detect colonic lesions 
[35], male gender and FIT haemoglobin concentration can be used as predictors of risk 
of advanced neoplasia and colorectal cancer and to prioritise colonoscopy in patients with 
positive FIT, both in screening and in symptomatic patients. The need to prioritize 
patients for colonoscopy is justified based on data that suggest that delays in reaching a 
CRC diagnosis is associated with worse prognosis, and on the presence of waiting list 
that can be as long as 6 months (or even longer) in some public universal health systems 
[28,29]. 
 
  
Pr vis
i l
References 
1. Globocan. Estimated cancer incidence, mortality and prevalence worldwide in 
2018. (2018). Available from: URL: https://gco.iarc.fr/ 
2. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of 
colorectal cancer screening: a systematic review for the U.S. Preventive Services 
Task Force. Ann Intern Med 2002; 137:96-104 
3. Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, Church 
TR. Long-term mortality after screening for colorectal cancer. N Engl J Med 
2013; 369: 1106-1114 doi: 10.1056/NEJMoa1300720 
4. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, 
Schuman LM. The effect of fecal occult-blood screening on the incidence of 
colorectal cancer. N Engl J Med 2000; 343: 1603-1607 doi: 
10.1056/NEJM200011303432203 
5. Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, Kuipers 
EJ. Colorectal cancer screening: a global overview of existing programmes. Gut 
2015; 64: 1637-1649 doi: 10.1136/gutjnl-2014-309086 
6. Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population 
screening programs worldwide in 2016: An update. World J Gastroenterol 2017; 
23: 3632-3642 doi: 10.3748/wjg.v23.i20.3632 
7. Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests 
versus guaiac faecal occult blood tests: what clinicians and colorectal cancer 
screening programme organisers need to know. Gut 2015; 64: 1327-1337 doi: 
10.1136/gutjnl-2014-308074 
8. Cubiella J, Salve M, Díaz-Ondina M, et al. Diagnostic accuracy of the faecal 
immunochemical test for colorectal cancer in symptomatic patients: comparison 
with NICE and SIGN referral criteria. Colorectal Dis. 2014;16(8): O273-82 doi: 
10.1111/codi.12569 
9. Westwood M, Lang S, Armstrong N, et al. Faecal immunochemical tests (FIT) 
can help to rule out colorectal cancer in patients presenting in primary care with 
lower abdominal symptoms: a systematic review conducted to inform new NICE 
DG30 diagnostic guidance. BMC Med. 2017;15(1):189 doi: 10.1186/s12916-017-
0944-z 
10. Westwood M, Corro Ramos I, Lang S, et al. Faecal immunochemical tests to 
triage patients with lower abdominal symptoms for suspected colorectal cancer 
Pr vis
on l
referrals in primary care: a systematic review and cost-effectiveness analysis. 
Health Technol Assess. 2017;21(33):1-234 doi: 10.3310/hta21330. 
11. Grazzini G, Visioli CB, Zorzi M, Ciatto S, Banovich F, Bonanomi AG, et al. 
Immunochemical faecal occult blood test: number of samples and positivity 
cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009; 
100: 259-265 doi: 10.1038/sj.bjc.6604864 
12. Hamza S, Dancourt V, Lejeune C, Bidan JM, Lepage C, Faivre J. Diagnostic yield 
of a one sample immunochemical test at different cut-off values in an organised 
screening programme for colorectal cancer. Eur J Cancer 2013; 49: 2727-2733 
doi: 10.1016/j.ejca.2013.03.023 
13. Young GP, Erin L, Seaman HE, et al. Advances in fecal occult blood tests: The 
FIT revolution. Dig Dis Sci. 2015;60:609-622 doi: 10.1007/s10620-014-3445-3 
14. Chiang TH, Lee YC, Tu CH, et al. Performance of the immunochemical fecal 
occult blood test in predicting lesions in the lower gastrointestinal tract. CMAJ. 
2011;183:1474-1481 doi: 10.1503/cmaj.101248 
15. Ciatto S, Martinelli F, Zappa M, et al. Association of FOBT-assessed faecal Hb 
content with colonic lesions detected in the Florence screening programme. 
British Journal of Cancer. 2007;96:218-221 doi: 10.1038/sj.bjc.6603534 
16. Vilkin A, Rozen P, Levi Z, Maoz E, Birkenfeld S, Niv Y. Performance 
characteristics and evaluation of an automated-developed and quantitative, 
immunochemical, fecal occult blood screening test. J Gastrentorol. 
2005;100:2519-2525 doi: 10.1111/j.1572-0241.2005.00231.x 
17. Liao CS, Lin YM, Chang HC, et al. Application of quantitative estimates of fecal 
hemoglobin concentration for risk prediction of colorectal neoplasia. World J 
Gastroenterol. 2013; 19:8366–72 doi: 10.3748/wjg.v19.i45.8366 
18. Auge JM, Pellise M, Escudero JM, et al. Risk stratification for advanced 
colorectal neoplasia according to fecal hemoglobin concentration in a colorectal 
cancer screening program. Gastroenterology 2014;147, 628–36.e1 doi: 
10.1053/j.gastro.2014.06.008 
19. Yen AM, Chen SL, Chiu SY, et al. A new insight into fecal hemoglobin 
concentration-dependent predictor for colorectal neoplasia. Int J Cancer. 2014; 
135:1203–12 doi: 10.1002/ijc.28748 
20. Garcia M, Mila N, Binefa G, et al. Fecal hemoglobin concentration as a measure 
of risk to tailor colorectal cancer screening: are we there yet. Eur J Cancer Prev. 
2015; 24:321–7 doi: 10.1097/CEJ.0000000000000090 
Provis
i nal
21. Cubiella J, Digby J, Rodríguez-Alonso L, et al. The fecal hemoglobin 
concentration, age and sex test score: Development and external validation of a 
simple prediction tool for colorectal cancer detection in symptomatic patients. Int 
J Cancer. 2017;1 40:2201-2211 doi: 10.1002/ijc.30639 
22. Cubiella J, Vega P, Salve M. Development and external validation of a faecal 
immunochemical test-based prediction model for colorectal cancer detection in 
symptomatic patients. BMC Med. 2016;14:128 doi: 10.1186/s12916-016-0668-5 
23. Godber IM, Todd LM, Fraser CG, MacDonald LR, Younes H Ben. Use of a faecal 
immunochemical test for haemoglobin can aid in the investigation of patients with 
lower abdominal symptoms. Clin Chem Lab Med. 2016; 54:595-602 doi: 
10.1515/cclm-2015-0617 
24. Atkin WS, Valori R, Kuipers EJ, et al.International Agency for Research on 
Cancer. European guidelines for quality assurance in colorectal cancer screening 
and diagnosis. First Edition--Colonoscopic surveillance following adenoma 
removal. Endoscopy. 2012;44 Suppl 3:SE151-63. 
25. Hassan C, Quintero E, Dumonceau JM, et al. European Society of Gastrointestinal 
Endoscopy. Post-polypectomy colonoscopy surveillance: European Society of 
Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2013; 45:842-51. doi: 
10.1055/s-0033-1344548. 
26. Sobin LH, Gospodarowicz M, Wittekind C. TNM classification of malignant 
tumours. 7th ed. New York: Wiley-Blackwell, 2009. 
27. Joseph DA, Meester RG, Zauber AG, et al. Colorectal cancer screening: 
Estimated future colonoscopy need and current volume and capacity. Cancer. 
2016; 122:2479-86 doi: 10.1002/cncr.30070 
28. Esteva M, Leiva A, Ramos M, et al; DECCIRE GROUP. Factors related with 
symptom duration until diagnosis and treatment of symptomatic colorectal cancer. 
BMC Cancer. 2013; 13:87 doi: 10.1186/1471-2407-13-87 
29. Torring ML, Murchie P, Hamilton W, et al. Evidence of advanced stage colorectal 
cancer with longer diagnostic intervals: a pooled analysis of seven primary care 
cohorts comprising 11 720 patients in five countries.Br J Cancer. 2017; 117:888-
897 doi: 10.1038/bjc.2017.236 
30. Rodríguez-Alonso L, Rodríguez-Moranta F, Ruiz-Cerulla A, et al. An urgent 
referral strategy for symptomatic patients with suspected colorectal cancer based 
on a quantitative immunochemical faecal occult blood test. Dig Liver Dis. 2015;4: 
797-804 doi: 10.1016/j.dld.2015.05.004 
Provis
onal
31. Widlak MM, Thomas CL, Thomas MG, et al. Diagnostic accuracy of faecal 
biomarkers in detecting colorectal cancer and adenoma in symptomatic patients. 
Aliment Pharmacol Ther. 2017;45: 354-363 doi: 10.1111/apt.13865 
32. Turvill J, Mellen S, Jeffery L, et al. Diagnostic accuracy of one or two faecal 
haemoglobin and calprotectin measurements in patients with suspected colorectal 
cancer. Scand J Gastroenterol. 2018;53: 1526-1534 doi: 10.1080/ 00365521.2018. 
1539761 
33. Rex DK, Schoenfeld PS, Cohen J, Pike IM, Adler DG, Fennerty MB, Lieb JG, 
Park WG, Rizk MK, Sawhney MS, Shaheen NJ, Wani S, Weinberg DS. Quality 
indicators for colonoscopy. Am J Gastroenterol 2015; 110: 72-90 doi: 
10.1038/ajg.2014.385 
34. Corley DA, Jensen CD, Marks AR, Zhao WK, Lee JK, Doubeni CA, et al. 
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 
2014; 370: 1298-1306 doi: 10.1056/NEJMoa1309086 
35. Ford AC, Veldhuyzen van Zanten SJ, Rodgers CC, et al. Diagnostic utility of 
alarm features for colorectal cancer: systematic review and meta-analysis. Gut. 
2008; 57:1545-53 doi: 10.1136/gut.2008.159723 
  
Provis
ional
  
Table 1. Demographics and colonoscopy findings according to FIT indication 
 Global         
n=2742 
SCREENING 
GROUP                  
n=1515 
SYMPTOMATIC 
GROUP      
n=1227 
p value 
Sex (men) 1585 
(57.8%) 
931 (61.5%) 654 (53.3%) <0.001 
Age (Mean±SD) 6 .6±9.3 65.0±3.3 66.2±13.4 <0.001 
Colonoscopy findings    <0.001 
    Normal 1254 
(45.7%) 
577 (38.1%) 677 (55.2%)  
    Low-risk adenoma 384 (14.0%) 273 (18.0%) 111 (9.0%)  
    Intermediate-risk 
aadenomaadenoma 
630 (23.0%) 408 (26.9%) 222 (18.1%)  
    High-risk adenoma 267 (9.7%) 191 (12.6%) 76 (6.2%)  
    Cancer 207 (7.5%) 66 (4.4%) 141 (11.5%)  
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Table 2. Haemoglobin FIT values according to colonoscopy findings. Median (Q1-
Q3) 
 
Colonoscopy findings SCREENING GROUP 
n=1515 
SYMPTOMATIC GROUP 
n=1227 
p valuea 
    Normal 275.0 (169.5 – 572.0) 386.0 (189.5 – 1276.0) <0.001 
    Low-risk adenoma 264.0 (167.0 – 582.0) 356.0 (180.0 – 834.0) 0.038 
    Intermediate-risk adenoma 499.0 (230.0 – 1245.0) 674.5 (319.8–2837.0) 0.003 
    High-risk adenoma 1249.0 (515.0 – 5429.0) 1797.5 (384.3 – 6159.5) 0.996 
    Cancer 3604.5 (578.8 – 9451.8) 5845.0 (767.0 – 13967.0) 0.035 
p valueb <0.001 <0.001  
aComparison between “SCREENING GROUP” and “SYMPTOMATIC GROUP” groups. 
bComparison between colonoscopy findings within each group. 
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Table 3. Haemoglobin FIT values according to advanced neoplasia and colorectal 
cancer alone. Median (Q1-Q3). 
Advanced neoplasia  
(advanced adenoma 
+ cancer) 
Global                    
n=2742 
SCREENING 
GROUP                  
n=1515 
SYMPTOMATIC 
GROUP     
 n=1227 
p valuea 
Yes 765.0 (302.5-4543.0) 717.0 (271.5-3841.0) 1065.0 (394.0-5993.0) <0.001 
No 305.5 (178.8-740.0) 272.5 (169.0-572.3) 379.0 (189.0-1149.5) <0.001 
p valueb <0.001 <0.001 <0.001  
 
Colorectal 
cancer  
Global                    
n=2742 
SCREENING 
GROUP                  
n=1515 
SYMPTOMATIC  
GROUP       
 n=1227 
p valuea 
Yes 4906.0 (719.0-12699.0) 3604.5 (578.8-
9451.8) 
5845.0 (767.0-13967.0) 0.035 
No 394.0 (200.0-834.0) 353.0 (194.0-770.0) 439.0 (211.5-2101.0) <0.001 
p valueb <0.001 <0.001 <0.001  
aComparison between “SCREENING GROUP” and “SYMPTOMATIC GROUP” groups. 
bComparison between colonoscopy findings  within each group. 
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Table 4. A) Risk of advanced neoplasia (advanced adenoma + cancer) according to 
Hb quartil. OR (CI 95%).  
 
  Global                  
n=2742 
Range SCREENING 
GROUP                 
n=1515 
Range SYMPTOMATIC 
GROUP      
 n=1227 
Q1 <270 1 <196 1 <223 1 
Q2 270-430 1.42 (1.11 – 1.81) 
 
196 – 370 1.27 (0.93 – 1.74) 223 – 513 1.65 (1.12 – 2.42) 
Q3 431-1956 2.94 (2.33 – 3.71) 
 
371 – 769 2.58 (1.89 – 3.52) 514 –3321 
3321 
3.14 (2.17 – 4.53) 
Q4 ≥1957 5.52 (4.36 – 6.99) ≥770 5.80 (4.26 – 7.90) ≥3322 5.55 (3.84 – 8.01) 
 
B) Risk of colorectal cancer according to Hb quartil. OR (CI 95%) 
  Global                  
n=2742 
Range SCREENING 
GROUP                 
n=1515 
Range SYMPTOMATIC 
GROUP        
n=1227 
Q1 <270 1 <196 1 <223 1 
Q2 270-430 0.68 (0.33 – 1.38)  
 
196 – 370 0.70 (0.22 – 2.21)       223 – 513 0.75 (0.32 – 1.73)  
 Q3 431-1956 2.50 (1.45 – 4.32)  
 
371 – 769 2.05 (0.81 – 5.21)  514 – 3321 2.50 (1.28 – 4.87) 
Q4 ≥1957 8.11 (4.94 – 13.30)  ≥770 5.76 (2.55 – 13.01)  
 
≥3322 8.82 (4.80 – 16.21)  
 
 
  Provis
ional
Table 5. A) Risk of advanced neoplasia according to sex and haemoglobin quartile. 
Age-adjusted OR (CI95%). Reference Q1 women. 
 SCREENING GROUP                                       
n=1515 
SYMPTOMATIC GROUP                               
n=1227 
 Women Men Women Men 
Q1 1 2.34 (1.43 – 3.84)               1 2.88 (1.55 – 5.34)                
Q2 1.14 (0.66 – 1.96)              3.40 (2.08 – 5.55)               1.22 (0.62 – 2.43)            4.91 (2.74 – 8.81)               
Q3 2.85 (1.65 – 4.94)           5.37 (3.33 – 8.67)              3.17 (1.73 – 5.80)          9.41 (5.23 – 16.92)              
Q4 5.26 (3.07 – 9.00)       13.08 (8.11 – 21.10)             6.67 (3.62 – 12.29)     12.68 (7.13 – 22.55)             
 
 B) Risk of colorectal cancer according to sex and haemoglobin quartile. Age-
adjusted OR (CI95%). Reference Q1 women. 
 SCREENING GROUP                                       
n=1515 
SYMPTOMATIC GROUP                               
n=1227 
 Women Men Women Men 
Q1 1 1.01 (0.22 – 4.56)                1 2.75 (0.82 – 9.16)                
Q2 -            1.38 (0.33 – 5.88)              1.31 (0.34 – 5.01)            1.19 (0.31 – 4.51)               
Q3 0.46 (0.05 – 4.48)           2.79 (0.77 – 10.09)             2.67 (0.82 – 8.75)           6.11 (2.04 – 18.32)              
Q4 5.75 (1.58 – 20.89)        5.89 (1.76 – 19.66)              12.86 (4.37 – 37.83)        16.95 (5.96 – 48.21)             
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Table 6. A) Haemoglobin FIT values according to colonoscopy findings location 
(left-sided, right sided). Median (Q1-Q3) 
Colonoscopy findings SCREENING GROUP 
(n =  1490) 
 
n=1515 
SYMPTOMATIC GROUP 
n=1227 
p valuea 
    No AN 272.5 (169.0-572.3) 379.0 (189.0-1149.5) <0.001 
    Left-sided AN  
 
765.0 (306.0-4227.0)  1505.0 (405.0-5983.5) 0.011 
    Right-sided AN 
 
648.0 (242.5-3276.5) 770.0 (329.0-7330.0) 0.001 
p valueb overall <0.001 <0.001  
p value no AN vs right-sided <0.001 <0.001  
p value no AN vs left-sided <0.001 <0.001  
p value right-sided vs left-sided 0.034 0.421  
aComparison between “SCREENING FIT” and “SYMPTOMATIC FIT” groups. bComparison 
between colonoscopy findings  within each group.  
 
B) Haemoglobin FIT values according to colorectal cancer location (left- sided, 
right-sided). Median (Q1-Q3) 
Colonoscopy findings SCREENING GROUP 
n=1515 
SYMPTOMATIC GROUP 
n=1227 
p valuea 
    No cancer  353.0 (194.0-770.0) 439.0 (211.5-2101.0) <0.001 
    Left-sided cancer  
 
2852.0 (533.8-8817.0) 5993.0 (768.5-15277.5) 0.029 
    Right-sided cancer 
 
6295.0 (713.0-9694.0) 4683.5 (628.0-12644.3) 0.569 
p valueb overall <0.001 <0.001  
p value no cancer vs right-sided <0.001 <0.001  
p value no cancer vs left-sided <0.001 <0.001  
p value right-sided vs left-sided 0.451 0.426  
aComparison between “SCREENING FIT” and “SYMPTOMATIC FIT” groups. bComparison 
between colonoscopy findings within each group. 
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Legends: Figure 1. Colonoscopy findings according to Hb quartile in (A) Screening 
group (p<0.001) and in (B) Symptomatic group (p<0.001). 
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Figure 2. PPV according to faecal haemoglobin concentration in (A) Screening 
group and in (B) Symptomatic group. 
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